Drug Pipeline

Pamiparib capsule Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
1
Recruiting
1
Phase 3
3
Top Sponsors
3
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-04 NCT04164199
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With…		 Trial completed
2026-06-04 NCT04164199
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With…		 date change Primary completion moved earlier: 2026-07 -> 2026-05-23
2026-06-04 NCT04164199
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With…		 date change Completion moved earlier: 2026-07 -> 2026-05-23
Active Studies by Phase
Phase 3
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT03519230 Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive… Ovarian Cancer Active, Not Recruiting
Phase 1
NCT05526924 Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With… Head and Neck Cancer Recruiting
NCT03749187 BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV… Glioblastoma Active, Not Recruiting
Sponsors Running Pamiparib capsule Trials
BeiGene (1) University of California, San Francisco (1) University of Chicago (1)
Disease Areas
Ovarian Cancer (1) Glioblastoma (1) Glioma (1) Head & Neck Cancer (1)
Get alerts when Pamiparib capsule trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free